· Published by Health Canada · Official notice
This is duplicated text of a letter from Novartis Pharmaceuticals Canada Inc.
Contact the company for a copy of any references, attachments or enclosures.
November 30, 2009
Subject: Use of EXJADEFootnote * (deferasirox) in Patients Diagnosed with Myelodysplastic Syndrome (MDS) and in Elderly Patients regarding Renal Events and Gastrointestinal Hemorrhage (Fatal in Rare Cases)
Dear Health Care Professional,
EXJADEFootnote * (deferasirox) is indicated in the management of chronic iron overload in patients with transfusion-dependent anemias aged 6 years or older. EXJADEFootnote * is also indicated in the management of chronic iron overload in patients with transfusion-dependent anemias aged two to five who cannot be adequately treated with deferoxamine.
Therapy with EXJADEFootnote * should be initiated and maintained by physicians experienced in the treatment of chronic iron overload due to blood transfusions.
In the review of death cases in the MDS patient population, it was apparent that approximately two-thirds of the deaths were in patients who had received less than six months of therapy, indicating that patients with advanced disease and a corresponding poor prognosis have been treated with EXJADEFootnote *. These patients are unlikely to derive benefit from treatment with EXJADEFootnote *.
In clinical trials, elderly patients experienced a higher frequency of adverse reactions than younger patients, and therefore should be monitored closely for adverse reactions that may require a dose adjustment.
Novartis has proposed changes to the Canadian Product Monograph that are currently under review by Health Canada. The proposed changes include (but are not limited to) the following:
Managing marketed health product related adverse reactions depends on health care professionals and consumers reporting them. Reporting rates determined on the basis of spontaneously reported post marketing adverse reactions are generally presumed to underestimate the risks associated with health product treatments. Any case of serious or unexpected adverse reactions in patients receiving EXJADEFootnote * should be reported to Novartis or Health Canada at the following addresses:
Novartis Pharmaceuticals Canada Inc.
385 Bouchard Blvd.
Dorval (QC) H9S 1A9
Telephone: 1-877-631-6775 x 3425 (Drug Safety & Epidemiology)
Any suspected adverse reaction can also be reported to:
Canada Vigilance Program
Marketed Health Products Directorate
HEALTH CANADA
Address Locator: 0701D
Ottawa, Ontario, K1A 0K9
Telephone: 613-957-0337 or Fax: 613-957-0335
To report an Adverse Reaction, consumers and health professionals may call toll free:
Telephone: 1-866-234-2345
Fax: 1-866-678-6789
CanadaVigilance@hc-sc.gc.ca
The Adverse Reaction Reporting Form and the Adverse Reaction Guidelines can be found on the Health Canada web site or in The Canadian Compendium of Pharmaceuticals and Specialties.
For other inquiries related to this communication, please contact Health Canada at:
Bureau of Metabolism, Oncology and Reproductive Sciences
Therapeutic Products Directorate
E-mail: BMORS_Enquiries@hc-sc.gc.ca
Telephone: 613-941-3171
Fax: 613-941-1365
Your professional commitment in this regard has an important role in protecting the well being of your patients by contributing to early signal detection and informed drug use.
Should you have medical enquiries regarding EXJADEFootnote *, please contact our Medical Information Department at 1-800-363-8883.
For more information please consult the EXJADEFootnote * Prescribing Information and Consumer Information on our Website.
Sincerely,
original signed by
Jean-Marie Leclerc, M.D. FRCP(C)
Chief Scientific Officer and Senior Vice-President Clinical and Regulatory Affairs
EXJADE is a registered trademark.